AT-13148(1056901-62-2）自研现货 98%

AT13148, a first-in-class multi-AGC kinase inhibitor, against gastric cancer cells. AT13148 exerted potent cytotoxic and anti-proliferative activities against a panel human gastric cancer cell lines (HGC-27, AGS, SNU-601, N87 and MKN-28), possibly via inducing cancer cell apoptotic death. Apoptosis inhibition by the Caspase blockers dramatically attenuated AT13148-caused cytotoxicity against gastric cancer cells. Intriguingly, same AT13148 treatment was not cytotoxic/pro-apoptotic to the non-cancerous human gastric epithelial GEC-1 cells. At the signaling level, AT13148 treatment in gastric cancer cells dramatically suppressed activation of multiple AGC kinases, including Akt (at p-Thr-308), p70S6 kinase (p70S6K), glycogen synthase kinase 3 (GSK-3) and p90 ribosomal S6 kinase (RSK). Our in vivo studies demonstrated that daily oral gavage of AT13148 at well-tolerated doses significantly inhibited HGC27 xenograft tumor growth in nude mice. AGC activity was also dramatically decreased in AT13148-administrated HGC27 tumors. Therefore, targeting AGC kinases by AT13148 demonstrates superior anti-gastric cancer activity both in vitro and in vivo. The preclinical results of this study support the progression of this molecule into future evaluation as a valuable anti-gastric cancer candidate.



其他产品详情可登陆官网www.sun-shinechem.com

武汉永璨生物科技有限公司是一家从事新药相关化合物、医药原料药、中间体、有机合成砌块、高端试剂等研发和销售的高新技术企业。我们提供的特色服务包括：手性药物的技术开发以及活性分子库的开发。 武汉永璨生物拥有1500多平方米的经营场所。研发实验室1000多平方米，配备多种研发实验室设备。质控管理实验室200多平方米，配备高效液相色谱仪、数显熔点仪、数显旋光仪、紫外分光光度计等，建有1公斤级中级实验室，可确保客户需求不断增长，顺利上市生产。公司与武汉大学武汉生物技术研究所建立了良好的合作关系，开展了多种创造性的研发合作活动，可以方便地使用他们的核磁共振、质谱、液质联用、单晶衍射等精密仪器用于研究。 公司已具备的仪器设备等硬件条件，充分满足各类项目的生产需求。武汉永璨生物注重专业技术人才的引进和培养。从研发到生产、销售，我们建立了一套科学的管理体系。研发中心采用项目管理制度，为每个研发项目设立项目负责人，并配备研发团队负责产品开发。我们依靠先进的设备和严格的管理为每一位客户提供优质的产品和服务！